sigletic
zakłady farmaceutyczne polpharma s.a. - sitagliptinas - plėvele dengtos tabletės - 100 mg - sitagliptin
rinvoq
abbvie deutschland gmbh & co. kg - upadacitinib - artritas, reumatas - imunosupresantai - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
giapreza
paion deutschland gmbh - angiotenzino ii acetatas - hypotension; shock - renino ir angiotenzino sistemos veikiantys vaistai - giapreza fluorouracilu ir folino ugniai atsparių hipotenzija suaugusiems su septinių ar kitus paskirstymo šoko, kurie lieka hypotensive nepaisant tinkamo tūrio restitucijos taikymo ir katecholaminų ir kitų galimų vasopressor terapija.
maysiglu
krka, d.d., novo mesto - sitagliptinas - plėvele dengtos tabletės - 25 mg - sitagliptin
maysiglu
krka, d.d., novo mesto - sitagliptinas - plėvele dengtos tabletės - 50 mg - sitagliptin
maysiglu
krka, d.d., novo mesto - sitagliptinas - plėvele dengtos tabletės - 100 mg - sitagliptin
adimuplan
sandoz d.d. - sitagliptinas - plėvele dengtos tabletės - 25 mg - sitagliptin
adimuplan
sandoz d.d. - sitagliptinas - plėvele dengtos tabletės - 50 mg - sitagliptin
adimuplan
sandoz d.d. - sitagliptinas - plėvele dengtos tabletės - 100 mg - sitagliptin
eprocliv
sandoz d.d. - sitagliptinas/metformino hidrochloridas - plėvele dengtos tabletės - 50 mg/850 mg - sitagliptin